Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 6:24 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 865–888 of 79,237 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: 2 Clear all
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of a Live-attenuated Universal Flu Vaccine Followed by an Inactivated Universal Flu Vaccine

NCT03300050
View directory record Official record
Conditions
Influenza, Vaccine
Interventions
cH8/1N1 LAIV, AS03-adjuvanted cH5/1N1 IIV, cH5/1N1 IIV, AS03-adjuvanted cH8/1N1 IIV, Normal saline, Phosphate buffered saline (PBS)
Biological
Lead sponsor
PATH
Other
Eligibility
18 Years to 39 Years
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
2
States / cities
Durham, North Carolina • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 21, 2021 · Synced Oct 31, 2026, 6:24 PM EDT
Completed Phase 3 Interventional Results available

Evaluation of Ixekizumab Using Auto-Injector or Prefilled Syringe in Participants With Moderate to Severe Plaque Psoriasis

NCT01777191
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Ixekizumab Auto-Injector, Ixekizumab Prefilled Syringe
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
22
States / cities
Anaheim, California • Bakersfield, California • Santa Monica, California + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2019 · Synced Oct 31, 2026, 6:24 PM EDT
Completed Not applicable Interventional

Virtual Weight Control Program Tailored for Adults With Type 2 Diabetes (VITAL)

NCT04804774
View directory record Official record
Conditions
Type2 Diabetes, Overweight and Obesity
Interventions
WW program modified for people with Type 2 diabetes
Behavioral
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
18 Years to 70 Years
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
3
States / cities
Gainesville, Florida • Baton Rouge, Louisiana • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 21, 2022 · Synced Oct 31, 2026, 6:24 PM EDT
Completed Phase 3 Interventional Results available

A Research Study to Show the Effect of Aprocitentan in the Treatment of Difficult to Control (Resistant) High Blood Pressure (Hypertension) and Find Out More About Its Safety

NCT03541174
View directory record Official record
Conditions
Resistant Hypertension
Interventions
Aprocitentan 12.5 mg, Aprocitentan 25 mg, Placebo
Drug
Lead sponsor
Idorsia Pharmaceuticals Ltd.
Industry
Eligibility
18 Years and older
Enrollment
730 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
41
States / cities
Alexander City, Alabama • Inglewood, California • Lincoln, California + 37 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2023 · Synced Oct 31, 2026, 6:24 PM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Efficacy and Safety of Brivaracetam as Treatment for Increased Seizure Activity in an Epilepsy Monitoring Unit Setting

NCT03021018
View directory record Official record
Conditions
Epilepsy
Interventions
Brivaracetam, Lorazepam
Drug
Lead sponsor
UCB Biopharma S.P.R.L.
Industry
Eligibility
18 Years to 70 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
14
States / cities
Birmingham, Alabama • Tucson, Arizona • Orlando, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2020 · Synced Oct 31, 2026, 6:24 PM EDT
Completed Not applicable Interventional Results available

HIRREM in Military Personnel

NCT03230890
View directory record Official record
Conditions
Stress Disorders, Post-Traumatic
Interventions
HIRREM
Device
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 14, 2023 · Synced Oct 31, 2026, 6:24 PM EDT
Not yet recruiting Phase 1 Interventional

A Study of LY3873862 in Participants With Sporadic or Familial Amyotrophic Lateral Sclerosis (ALS).

NCT07883590
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, Cytochrome P-450 Enzyme System
Interventions
LY3873862, CYP450 Drug Cocktail, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
3
States / cities
San Francisco, California • Aurora, Colorado • Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 31, 2026, 6:24 PM EDT
Completed No phase listed Observational

Non-Invasive Imaging of Atherosclerosis

NCT01418313
View directory record Official record
Conditions
Atherosclerosis
Interventions
Not listed
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
20 Years and older
Enrollment
886 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 3, 2020 · Synced Oct 31, 2026, 6:24 PM EDT
Terminated Phase 2 Interventional Results available

A Study of Avelumab in Combination With Axitinib In Non-Small Cell Lung Cancer (NSCLC) or Urothelial Cancer (Javelin Medley VEGF)

NCT03472560
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, Urothelial Cancer
Interventions
Avelumab (MSB0010718C), Axitinib (AG-013736)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
14
States / cities
Glendale, Arizona • Goodyear, Arizona • Phoenix, Arizona + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2024 · Synced Oct 31, 2026, 6:24 PM EDT
Completed Not applicable Interventional

Explore Transplant at Home: Improving Low-Income ESRD Patients' Transplant Knowledge

NCT02268682
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Patient-Guided, Educator-Guided
Other
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years to 74 Years
Enrollment
558 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 28, 2023 · Synced Oct 31, 2026, 6:24 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety and Efficacy of Intravenous JNJ-64179375 Versus Oral Apixaban in Participants Undergoing Elective Total Knee Replacement Surgery

NCT03251482
View directory record Official record
Conditions
VTE Prophylaxis With Anticoagulation After Total Knee Replacement Surgery
Interventions
JNJ-64179375 0.3 mg/kg, JNJ-64179375 0.6 mg/kg, JNJ-64179375 1.2 mg/kg, JNJ-64179375 (Dose to be Determined), JNJ-64179375 A mg/kg, JNJ-64179375 B mg/kg, JNJ-64179375 C mg/kg, JNJ-64179375 D mg/kg, Placebo JNJ-64179375, Apixaban placebo, Apixaban 2.5 mg
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
50 Years and older
Enrollment
308 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
7
States / cities
Phoenix, Arizona • Torrance, California • Englewood, Colorado + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2019 · Synced Oct 31, 2026, 6:24 PM EDT
Recruiting Not applicable Interventional

Powered Prosthesis for Use With TF Osseointegration Recipients

NCT06160882
View directory record Official record
Conditions
Amputation
Interventions
Powered Prosthesis Training and EMG data collection, Perform Osseointegration (OI) surgery and Targeted Muscle Reinnervation (TMR)
Other · Procedure
Lead sponsor
Shirley Ryan AbilityLab
Other
Eligibility
18 Years to 70 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 18, 2025 · Synced Oct 31, 2026, 6:24 PM EDT
Completed Phase 4 Interventional Results available

Drug-Eluting Stents vs. Bare Metal Stents In Saphenous Vein Graft Angioplasty

NCT01121224
View directory record Official record
Conditions
Saphenous Vein Graft Atherosclerosis
Interventions
Bare Metal Stent, Drug-Eluting Stent, Blinded clopidogrel, Placebo, Thienopyridine (open-label)
Device · Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
597 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
25
States / cities
Tucson, Arizona • Little Rock, Arkansas • San Francisco, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2022 · Synced Oct 31, 2026, 6:24 PM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

This Study is Evaluating a New Radiation Treatment Technique for Patients Who Have Had Prostate Cancer, Undergone Surgery for Cancer, and Then Have Evidence That Their Prostate Cancer Has Returned.

NCT05946824
View directory record Official record
Conditions
Recurrent Prostate Cancer After Surgery
Interventions
Daily-adaptive Stereotactic Body Radiation Therapy
Radiation
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older · Male only
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Oct 8, 2024 · Synced Oct 31, 2026, 6:24 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

A Study of the Safety and Activity of Eculizumab in Pediatric Participants With Relapsing Neuromyelitis Optica Spectrum Disorder

NCT04155424
View directory record Official record
Conditions
Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder
Interventions
Eculizumab
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
Not listed
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
15
States / cities
San Francisco, California • Washington D.C., District of Columbia • Miami, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2024 · Synced Oct 31, 2026, 6:24 PM EDT
Withdrawn Phase 2 Interventional

Neoadjuvant KRAS G12C Directed Therapy With Adagrasib (MRTX849) With or Without Nivolumab

NCT05472623
View directory record Official record
Conditions
Resectable Non-Small Cell Lung Cancer
Interventions
Adagrasib, Adagrasib/Nivolumab
Drug · Combination Product
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 15, 2025 · Synced Oct 31, 2026, 6:24 PM EDT
Completed Not applicable Interventional Results available

GLYCOSA Study:Effect of PAP Treatment on Glycemic Control in Patients With Type 2 Diabetes

NCT00509223
View directory record Official record
Conditions
Diabetes Mellitus Type 2
Interventions
Positive Airway Pressure therapy, Lifestyle counseling
Device · Behavioral
Lead sponsor
ResMed
Industry
Eligibility
18 Years and older
Enrollment
416 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
11
States / cities
Mission Viejo, California • Temecula, California • Coral Gables, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2013 · Synced Oct 31, 2026, 6:24 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Growth Hormone and Chromosome 18q- and Abnormal Growth

NCT00134420
View directory record Official record
Conditions
Loss of Chromosome 18q, Growth Hormone Deficiency
Interventions
Nutropin AQ, Arginine and Clonidine Stimulation Testing, Growth Factors Laboratory Testing, Neuropsychological Testing
Drug · Procedure
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
Up to 18 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2005
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 8, 2016 · Synced Oct 31, 2026, 6:24 PM EDT
Completed Not applicable Interventional

Opening the Conversation Study

NCT04806724
View directory record Official record
Conditions
Breast Cancer, Gynecologic Cancer
Interventions
Opening the Conversation, Side by Side
Behavioral
Lead sponsor
Oregon State University
Other
Eligibility
18 Years and older
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Corvallis, Oregon
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Oct 31, 2026, 6:24 PM EDT
Completed Phase 2 Interventional

A Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab as Adjunct Treatment in Prevention of Vaso-Occlusive Episodes (VOE) in Sickle Cell Disease (SCD)

NCT05075824
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Crovalimab, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
12 Years to 55 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
4
States / cities
Detroit, Michigan • Madison, Mississippi • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Oct 31, 2026, 6:24 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Research and Innovation to Stop E-cigarette/Vaping in Young Adults

NCT04974580
View directory record Official record
Conditions
Nicotine Dependence, E-Cig Use
Interventions
Nicotine patch, Phone Counseling, Digital Coaching
Drug · Behavioral
Lead sponsor
Ohio State University
Other
Eligibility
18 Years to 24 Years
Enrollment
508 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 29, 2024 · Synced Oct 31, 2026, 6:24 PM EDT
Completed Phase 2 Interventional Results available

Phase 2 Study of Temozolomide to Treat Poor Risk / Refractory Acute Myeloid Leukemia

NCT00611247
View directory record Official record
Conditions
Leukemia, Myeloid
Interventions
Temozolomide
Drug
Lead sponsor
Bruno C. Medeiros
Other
Eligibility
60 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 15, 2018 · Synced Oct 31, 2026, 6:24 PM EDT
Completed Phase 2 Interventional Results available

Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS)

NCT01709149
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
CK-2017357, Placebo tablets, Riluzole
Drug · Other
Lead sponsor
Cytokinetics
Industry
Eligibility
18 Years and older
Enrollment
711 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
44
States / cities
Phoenix, Arizona • La Jolla, California • Orange, California + 38 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2020 · Synced Oct 31, 2026, 6:24 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Use of an Herbal Preparation to Prevent and Dissolve Kidney Stones

NCT00381849
View directory record Official record
Conditions
Cystinuria, Nephrolithiasis, Calcium Oxalate
Interventions
Cystone, Sugar Pill (Placebo)
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 100 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 4, 2016 · Synced Oct 31, 2026, 6:24 PM EDT